AbbVie announced that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.
"With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "The addition of CPTX2309 and Capstan's tLNP platform strengthens our ability to deliver new treatments aimed at resetting the immune system and enables application of Capstan's proprietary technology more broadly for in vivo programming of cells."
Comments powered by CComment